Search results for " Asthma exacerbations"

showing 3 items of 3 documents

Therapeutic effects of benralizumab assessed in patients with severe eosinophilic asthma: Real-life evaluation correlated with allergic and non-aller…

2021

Corrado Pelaia,1 Claudia Crimi,2 Alida Benfante,3 Maria Filomena Caiaffa,4 Cecilia Calabrese,5 Giovanna Elisiana Carpagnano,6 Domenico Ciotta Jnr,7 Maria D’Amato,8 Luigi Macchia,9 Santi Nolasco,2 Girolamo Pelaia,1 Simona Pellegrino,7 Nicola Scichilone,3 Giulia Scioscia,10 Giuseppe Spadaro,11 Giuseppe Valenti,12 Alessandro Vatrella,7 Nunzio Crimi2 1Department of Health Sciences, University “Magna Graecia” of Catanzaro, Catanzaro, Italy; 2Department of Clinical and Experimental Medicine, University of Catania, Catania, Italy; 3Department of Biomedicine and Internal and Specialistic Medicine, University of Palermo, Palermo, Italy; 4Allergology and Clinical Immunol…

Pulmonary and Respiratory Medicinelcsh:Immunologic diseases. Allergymedicine.medical_specialtyVital capacityallergic and non allergic phenotypesAsthma exacerbationSettore MED/10 - Malattie Dell'Apparato Respiratoriobenralizumab.FEV1/FVC ratiochemistry.chemical_compoundPrednisoneInternal medicineIL-5 receptorJournal of Asthma and AllergyImmunology and AllergyMedicineClinical significanceAsthmaOriginal ResearchAllergic and non-allergic phenotypebusiness.industrySevere eosinophilic asthmaTherapeutic effectBenralizumabmedicine.diseaseBenralizumabchemistryasthma exacerbationsExhaled nitric oxideallergic and non-allergic phenotypesbusinesslcsh:RC581-607Allergic and non-allergic phenotypesAsthma exacerbations Benralizumab IL-5 receptor Severe eosinophilic asthmaAllergic and non-allergic phenotypes; Asthma exacerbations; Benralizumab; IL-5 receptor; Severe eosinophilic asthmamedicine.drug
researchProduct

Fluticasone propionate/formoterol: a fixed-combination therapy with flexible dosage.

2014

International guidelines describe asthma control as the main outcome of asthma management. Prevention of symptoms, improved quality of life, and reduction of exacerbations are the main components, consequently decreasing health care costs. However, many of these objectives remain unmet in real life: several surveys show that a large proportion of asthmatic patients are not well controlled despite the efficacy of current available treatment. Several randomized controlled clinical trials indicate that combining inhaled corticosteroids and long-acting β2-agonists, by means of a single inhaler, greatly improves the management of the disease. The results of 9 multicenter phase III clinical studi…

medicine.medical_specialtyCombination therapyAsthma exacerbationSettore MED/10 - Malattie dell'Apparato RespiratorioSettore MED/10 - Malattie Dell'Apparato RespiratorioFluticasone propionateAsthma control; Asthma exacerbations; Fixed-combination therapy; Fluticasone propionate/formoterol; Single-aerosol inhalerAsthma controlFluticasone propionate/formoterolForced Expiratory VolumeFormoterol FumarateInternal MedicineMedicineHumansAnti-Asthmatic AgentsAsthma exacerbationsParticle SizeIntensive care medicineAsthmaFluticasonebusiness.industryInhalerNebulizers and VaporizersFixed-combination therapyAsthma control; Asthma exacerbations; Fixed-combination therapy; Fluticasone propionate/formoterol; Single-aerosol inhaler; Androstadienes; Anti-Asthmatic Agents; Asthma; Bronchodilator Agents; Drug Combinations; Ethanolamines; Fluticasone; Forced Expiratory Volume; Formoterol Fumarate; Humans; Nebulizers and Vaporizers; Particle Size; Quality of Life; Treatment Outcomemedicine.diseaseSingle-aerosol inhalerAsthmaBronchodilator AgentsAndrostadienesDrug CombinationsTreatment OutcomeTolerabilityAsthma control Asthma exacerbations Fixed-combination therapy Fluticasone propionate/formoterol Single-aerosol inhalerEthanolaminesAnesthesiaAsthma exacerbations; Asthma control; Fixed-combination therapy; Fluticasone propionate/formoterol; Single-aerosol inhalerQuality of LifeFluticasoneFormoterol FumarateFormoterolbusinessmedicine.drugEuropean journal of internal medicine
researchProduct

Clinical evaluation and treatment of acute asthma exacerbations in children

2009

This update on treatment of asthma exacerbations in children is the result of an Italian Pediatric Society Task-force, made up of a panel of experts working in 2007–2008. The aim is to give clear indications on the use of the drugs most employed in children, grading the quality of evidence and the strength of recommendations. Suggestions on their limits due to unlicensed and off-label use are reported. The level of evidence and the strength of recommendations for different therapeutic approaches demonstrate that frequently the use of drugs in children is extrapolated from the experience in adults and that more studies are required to endorse the correct use of different drugs in asthmatic …

medicine.medical_specialtyImmunologyMEDLINESeverity of Illness Index; Acute Disease; Evidence-Based Medicine; Off-Label Use; Hospitalization; Humans; Treatment Outcome; Practice Guidelines as Topic; Asthma; Anti-Asthmatic Agents; Child; Child PreschoolOff-label useSeverity of Illness IndexSeverity of illnessHumansAnti-Asthmatic AgentImmunology and AllergyMedicineAnti-Asthmatic AgentsChildIntensive care medicineGrading (education)PharmacologyEvidence-Based MedicineAsthma exacerbationsbusiness.industryOff-Label UseEvidence-based medicineAsthmaHospitalizationQuality of evidenceacute asthma; children; emergency treatmentTreatment OutcomeSettore MED/38 - PEDIATRIA GENERALE E SPECIALISTICAChild PreschoolAcute DiseasePractice Guidelines as Topicacute asthma exacerbations in childrenbusinessacute asthma exacerbations in children.Clinical evaluationHuman
researchProduct